Targeted therapy for pediatric central nervous system tumors harboring mutagenic tropomyosin receptor kinases.

导出 LinkOut

翻译打印收藏纠错

第一作者： Selene,Cipri

第一单位： Department of Hematology/Oncology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children's Hospital, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.

作者： Selene,Cipri ^[1] ; Francesco,Fabozzi ^[1] ; Giada,Del Baldo ^[2] ; Giuseppe Maria,Milano ^[1] ; Luigi,Boccuto ^[3] ; Andrea,Carai ^[4] ; Angela,Mastronuzzi ^[1]

作者单位： Department of Hematology/Oncology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children's Hospital, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy. ^[1] Department of Hematology/Oncology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children's Hospital, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.;Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy. ^[2] Healthcare Genetics Program, School of Nursing, College of Behavioral, Social and Health Sciences, Clemson University, Clemson, SC, United States. ^[3] Department of Neurosciences, Neurosurgery Unit, Bambino Gesù Children's Hospital, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy. ^[4]

关键词 NTRK acquired resistance central nervous system tumors gene fusions pediatric tumors point mutations targeted therapy tropomyosin receptor kinases

DOI 10.3389/fonc.2023.1235794

PMID 38144536

发布时间 2023-12-25

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交